AzTrials
AzTrials

Dual Use of Cigarettes and E-cigarettesNCT07124702

Cessation of Dual Use of Cigarettes and E-cigarettes During Pregnancy

A study testing Simultaneous cessation intervention, Stepwise cessation intervention and Behavior counseling only in people with Dual Use of Cigarettes and E-cigarettes and Gestational Weight Gain, run by State University of New York at Buffalo at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

We propose a randomized controlled trial to develop and evaluate a cessation program with two different strategies for dual users during pregnancy. We plan to enroll 45 pregnant mothers (≤20 gestational weeks) with low household incomes from the Western NY region. Read more about this study

Who is it for?
Ages 18 years and older, women only
What is being tested?
Simultaneous cessation intervention, Stepwise cessation intervention and Behavior counseling only
Could I receive a placebo?
No, everyone receives an active treatment
How many people
45 participants
Where
1 siteUnited States
Study dates
1 Oct 2025to 31 Mar 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Less than 21 weeks pregnant to ensure adequate time for intervention;
  • 18 years or older;
  • Actively using both cigarettes and electronic cigarettes (e-cigarettes);
  • Willing to receive cessation information;
  • Able to read, understand, and speak English;
  • Having a low household income defined as ≤185% of the federal poverty level.

Who cannot join

  • Teen pregnancy (<18 y);
  • Unstable housing;
  • Uncontrolled mental health disorders;
  • Non-English speakers.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Xiaozhong Wen, PhD contact

716-829-6811

xiaozhon@buffalo.edu

United States1 site, 1 recruiting
  • State University of New York at Buffalo

    Buffalo, New York, 14214

    Xiaozhong Wen, PhD, 716-829-6811, xiaozhon@buffalo.edu

    Xiaozhong Wen, PhD

    Recruiting

Other trials in United States

About this study

We propose a randomized controlled trial to develop and evaluate a cessation program with two different strategies for dual users during pregnancy. We plan to enroll 45 pregnant mothers (≤20 gestational weeks) with low household incomes from the Western NY region. To be eligible, they must be currently dual using CCs and nicotine-containing ECs. These mothers will be randomized into one of three groups: 1) simultaneous cessation intervention group (N=15), 2) stepwise cessation intervention group (N=15), and 3) control group (N=15). We hypothesize that nicotine abstinence rates at 8 weeks after randomization will be higher in the intervention groups than in the control group.

Read the detailed description

Study overview. We propose a pilot randomized controlled trial (RCT) to develop and test a cessation program for dual users during pregnancy. We will enroll 45 Western New York pregnant mothers (≤20 weeks gestational age) with low household incomes who are currently dual-using CCs and nicotine-containing ECs. These mothers will be randomized into one of three groups: 1) simultaneous cessation intervention (N=15), 2) stepwise cessation intervention (N=15), and 3) control group (N=15). Both intervention groups will receive a multi-component intervention, including behavior counseling, biomarker feedback, and contingent financial incentives for biochemically verified abstinence. However, the two intervention groups will have different orders of cessation targets: the simultaneous cessation group will target CCs and ECs at the same time, whereas the stepwise cessation group will first target CCs and then target ECs after quitting CCs. The control group will only receive behavior counseling. Mothers will be followed throughout pregnancy until delivery. The primary outcome is nicotine abstinence at 8 weeks after randomization.

Randomization. After the pre-test visit, participants who are still dual using CCs and ECs will be randomized into one of three groups: 1) simultaneous cessation intervention group, 2) stepwise cessation intervention group, and 3) control group. A computer will be used to generate balanced-permuted blocks with a block size of 9 and a 3-3-3 ratio, which can ensure equal numbers of participants across the three groups throughout the project. The study biostatistician will create the sequences a priori and then apply them using a workflow and database software system.

Sample size. Based on the literature and our previous intervention, we estimate the dual-use nicotine abstinence rate at 8 weeks after randomization (the primary maternal outcome) to be 30% in the intervention groups versus 10% in the control group. Accordingly, we need 62 participants per group to detect a significant difference in nicotine abstinence with 80% power at a significance level of 0.05 (Aim 1). Therefore, 15 participants per group for this pilot study should provide a sufficient sample size to test study feasibility, recruitment, and retention and yield preliminary data on intervention efficacy and the magnitude of group differences in health outcomes to support an NIH R01 grant application for a large project.

Statistical analysis. We will first conduct descriptive analyses to determine if transformations are necessary, and then run bivariate analyses. We will compare the distributions of covariates above across the 3 randomized groups. Only the unbalanced covariates that predict smoking/vaping abstinence will be controlled in data analyses. We will use Intention-to-Treat analysis, i.e., including all women as assigned at randomization. Multiple imputations with 20 replicates will be used to impute missing data on outcomes or covariates.36 Sensitivity analysis will be conducted by conservatively assuming participants lost in the follow-up to be current dual users.

We will use Chi-square tests to compare categorical outcomes (e.g., maternal nicotine abstinence rates) and analysis of variance to compare continuous outcomes (e.g., infant birth-weight-for-gestational-age z-score) across groups. Then, we will use multivariable logistic and linear regression models to fit categorical and continuous outcomes, respectively. A propensity score approach will be used to control confounders, including socio-demographics, pregnancy-related characteristics, and other substance use. The model will include group assignment (simultaneous cessation intervention vs. control, stepwise cessation intervention vs. control, or simultaneous vs. stepwise cessation intervention), fidelity of intervention delivery, adherence to intervention, and a propensity score derived from all unbalanced covariates. We will estimate the group differences in nicotine abstinence rates and odds ratios from the regression model.

Being tested
Simultaneous cessation intervention, Stepwise cessation intervention, Behavior counseling only
Keywords
Randomized Controlled Trial, Tobacco use, Electronic cigarette, Pregnancy, Intervention
Medical subject headings
Vaping, Gestational Weight Gain, Tobacco Use

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Simultaneous cessation interventionBehavioural

    This simultaneous cessation intervention group will target CCs and ECs at the same time. Participants in this group will receive a multi-component cessation intervention, including behavior counseling, biomarker feedback via monitoring changes in levels of exposure to nicotine (urine cotinine) and CC smoke (breath carbon monoxide), and contingent financial incentives for biochemically verified abstinence.

  • Stepwise cessation interventionBehavioural

    This stepwise cessation intervention group will first target CCs and then target ECs after quitting CCs. Participants in this group will receive a multi-component cessation intervention, including behavior counseling, biomarker feedback via monitoring changes in levels of exposure to nicotine (urine cotinine) and CC smoke (breath carbon monoxide), and contingent financial incentives for biochemically verified abstinence.

  • Behavior counseling onlyBehavioural

    Participants assigned to the control group will receive behavior counseling only. They will complete the same number of study visits as their counterparts in the intervention groups.

Study groups in NCT07124702
Study groupRoleWhat they receive
Simultaneous cessation interventionExperimentalThis simultaneous cessation intervention group will target CCs and ECs at the same time. Participants in this group will receive a multi-component cessation intervention, including behavior counseling, biomarker feedback via monitoring changes in levels of exposure to nicotine (urine cotinine) and CC smoke (breath carbon monoxide), and contingent financial incentives for biochemically verified abstinence.
Receives: Behavioral: Simultaneous cessation intervention
Stepwise cessation interventionExperimentalThis stepwise cessation intervention group will first target CCs and then target ECs after quitting CCs. Participants in this group will receive a multi-component cessation intervention, including behavior counseling, biomarker feedback via monitoring changes in levels of exposure to nicotine (urine cotinine) and CC smoke (breath carbon monoxide), and contingent financial incentives for biochemically verified abstinence.
Receives: Behavioral: Stepwise cessation intervention
Control groupActive comparatorParticipants assigned to the control group will receive behavior counseling only. They will complete the same number of study visits as their counterparts in the intervention groups.
Receives: Behavioral: Behavior counseling only

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Nicotine abstinence

    Research staff who are blinded to the participant's group assignment will administer a timeline follow-back interview (trained by the PI, Dr. Wen) to assess the participant's recent smoking and vaping history. Based on self-reports, we will classify smoking and vaping status in the past 7 days (7-day point prevalence) prior to the outcome assessment visits at pre-test, 8 weeks after randomization, and at the end of pregnancy. To confirm self-reported complete nicotine abstinence (i.e., abstinence from both ECs and CCs), 5.0 mL of urine samples will be collected at study visits in the 8th week after randomization and at the end of pregnancy (approximately 35 weeks). An HPLC-MS/MS assay will be used as a gold standard test to determine urine cotinine levels.

    Measured: 8 weeks after randomization, at the end of pregnancy

Secondary outcomes (3)
  1. The time needed to achieve nicotine abstinence

    We define the time needed to achieve nicotine abstinence as the interval between the day of randomization and the first day of complete nicotine abstinence ("not even a puff") without any relapse until birth delivery.

    Measured: 8 weeks after randomization, at the end of pregnancy

  2. The mother's gestational weight gain

    Total gestational weight gain (GWG) will be calculated as the difference between weight right before delivery and pre-pregnancy weight. Based on 2009 the Institute of Medicine (IOM) guidelines, we will define inadequate GWG as total GWG less than 28, 25, 15, and 11 pounds for underweight (pre-pregnancy BMI<18.5 kg/ m2), normal weight (BMI 18.5-24.9), overweight (BMI 25-29.9), and obese mothers (BMI ≥30), respectively.

    Measured: Right before delivery

  3. The infant's birth-weight-forgestational- age z score

    We will obtain the infant's gestational age, clinical measures on weight, length, and head circumference at birth from delivery records. Gestational age will be calculated as the interval between the self-reported last menstrual period and delivery date. We will calculate the infant's birth-weight-for-gestational-age z score and percentile for the same sex and gestational age. SGA will be defined as birth weight below the 10th percentile.

    Measured: At birth

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Aug 2025
  2. Study start1 Oct 2025
  3. Primary completion30 Sep 2026 (estimated)
  4. Study completion31 Mar 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
45 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07124702
Sponsor's protocol ID
STUDY00008644
Other IDs
UL1TR001412
Status last verified
Nov 2025
First submitted
9 Aug 2025
Last updated
13 Nov 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Confidentiality reasons.

Questions about this trial

What is this clinical trial studying?

A study testing Simultaneous cessation intervention, Stepwise cessation intervention and Behavior counseling only in people with Dual Use of Cigarettes and E-cigarettes and Gestational Weight Gain, run by State University of New York at Buffalo at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 13 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Xiaozhong Wen, PhD (716-829-6811, xiaozhon@buffalo.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Nicotine abstinence (time frame: 8 weeks after randomization, at the end of pregnancy). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Nov 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in